Estrone

Spezifikationen

53-16-7CAS-Nummer

200-164-5EG-Nummer

(8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-oneIUPAC-Name

C18H22O2Chemische Formel

270.4 g/molMolekulargewicht

estrone; 53-16-7; folliculin; Theelin; estrovarin; Thelykinin; Kestrone; Ketohydroxyestrin; Estrugenone; Tokokin; 1,3,5(10)-Estratrien-3-ol-17-one; Follicunodis; Disynformon; Glandubolin; Hiestrone; Oestroform; Oestroperos; Estron; Femidyn; Folipex; Folisan; Kolpon; Menagen; Oestrin; Endofolliculina; Aquacrine; Crinovaryl; Cristallovar; Crystogen; Hormofollin; Hormovarine; Ketodestrin; Menformon; Oestronum; Ovifollin; Thelestrin; Wynestron; Destrone; Estrusol; Perlatan; 3-Hydroxyestra-1,3,5(10)-trien-17-one; Folikrin; Follestrine; Solliculin; Thynestron; Femestrone injection; Estrona; Estrogenic Substance; Estra-1,3,5(10)-trien-17-one, 3-hydroxy-; Folliculinum; Estronum; 3-Hydroxy-17-keto-estra-1,3,5-triene; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; 1,3,5(10)-Oestratrien-3-ol-17-one; 3-Hydroxy-17-keto-oestra-1,3,5-triene; delta-1,3,5-estratrien-3-beta-ol-17-one; DTXSID4022367; delta-1,3,5-oestratrien-3-beta-ol-17-one; 3-Hydroxy-1,3,5(10)-estratrien-17-one; Estradiol metabolite e1; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; Unden (pharmaceutical); NATURAL ESTROGENIC SUBSTANCE-ESTRONE; 1,3,5-Estratrien-3-ol-17-one; NSC-9699; 3-hydroxy-estra-1,3,5(10)-trien-17-one; 2DI9HA706A; WAY 164397; DTXCID402367; CHEBI:17263; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta(a)phenanthren-17-one; Estrone 1516; RefChem:5805; G03CA07; G03CC04; (1S,10R,11S,15S)-5-hydroxy-15-methyltetracyclo(8.7.0.02,7.011,15)heptadeca-2(7),3,5-trien-14-one; 200-164-5; OESTRONE; Folliculine; Hormestrin; Unden; Estrone-A; Ketohydroxyoestrin; estrol; Estrona [Spanish]; Folliculine benzoate; Ovex (tablets); Estronum [INN-Latin]; Estrona [INN-Spanish]; Follestrol; Mestronaq; (+)-Estrone; Ketohydroxy-Estratriene; 3-Hydroxyestra-1,3,5(10)-triene-17-one; Estrone (E1); delta-1,3,5-Estratrien-3beta-ol-17-one; Fem-O-Gen; (+/-)-Oestrone; delta-1,3,5-Oestratrien-3beta-ol-17-one; (+/-)-Estrone; Estrone DL-form [MI]; Estrone, (+/-)-; 19973-76-3; Estrone (Standard); E(sub 1); MFCD00003620; CHEMBL1405; MLS000028475; X9XKA379T9; Estra-1,3,5(10)-trien-17-one, 3-hydroxy-, (+/-)-; SMR000058338; Unigen; [2,4,6,7-3H]-E1; hydroxyestrones; Unden (pharmaceutical) (VAN); (9beta,13alpha)-3-Hydroxyestra-1,3,5(10)-Trien-17-One; Oestrone [Steroidal oestrogens]; (1S,10R,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-trien-14-one; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; CCRIS 285; HSDB 3324; (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; NSC 9699; EINECS 200-164-5; Estrone (JAN/USP/INN); Estrone [USP:INN:BAN]; BRN 1915077; UNII-2DI9HA706A; UNII-X9XKA379T9; Aquest; Menformon;; Oestrone;; Oestrin;; Estrone RS; Estrone CRS; Oxohydroxyoestrin;; CAS-53-16-7; NCGC00015423-03; Follicular hormone;; J3Z; CMC_13458; Estrone, 15; ESTRONE [VANDF]; Opera_ID_330; ESTRONE [HSDB]; Estrone, >=99%; ESTRONE [INN]; ESTRONE [JAN]; ESTRONE [MI]; ESTRONE [MART.]; Prestwick0_000914; Prestwick1_000914; Prestwick2_000914; Prestwick3_000914; Spectrum5_002047; E0026; ESTRONE [USP-RS]; ESTRONE [WHO-DD]; 3-hydroxy-estra-1,3,5(10)-triene-17-one; bmse000549; E 9750; EC 200-164-5; FOLLICULINUM [HPUS]; Lopac0_000513; SCHEMBL21702; BSPBio_000788; 3-08-00-01171 (Beilstein Handbook Reference); MLS001077340; MLS002695951; MLS006011890; BIDD:ER0145; ESTRONE [ORANGE BOOK]; SPBio_002977; BPBio1_000868; GTPL2818; MEGxm0_000444; orb1310063; orb3025577; SGCUT00128; ESTRONE [USP MONOGRAPH]; Estrone 1.0 mg/ml in Methanol; SCHEMBL29373834; ACon0_000083; ACon1_000122; BDBM17289; HY-B0234R; [2,4,6,7-3H]-Estrone; MSK2214; Estriol EP Impurity B (Estrone); HMS1570H10; HMS2090E22; HMS2097H10; HMS2232O15; HMS3261H07; HMS3714H10; HY-B0234; to_000049; Tox21_113567; Tox21_201375; Tox21_303651; Tox21_500513; BL-090; EBC-04419; LMST02010004; MSK2214-100A; s1665; STK801833; AKOS005622512; AKOS007930641; MSK2214-1000A; Tox21_113567_1; AC-1395; CCG-204604; DB00655; DS-6316; Estrone 100 microg/mL in Acetonitrile; FE22839; LP00513; SDCCGSBI-0050497.P002; SMP1_000123; NCGC00023643-03; NCGC00023643-04; NCGC00023643-05; NCGC00023643-06; NCGC00023643-07; NCGC00023643-08; NCGC00023643-09; NCGC00023643-10; NCGC00023643-11; NCGC00023643-12; NCGC00023643-13; NCGC00023643-15; NCGC00023643-16; NCGC00023643-22; NCGC00179433-01; NCGC00179433-02; NCGC00179433-03; NCGC00257402-01; NCGC00258926-01; NCGC00261198-01; Estrone, meets USP testing specifications; SY036249; D1,3,5(10)-Estratrien-3-ol-17-one; 3-hydroxyl-1,3,5(10)-estratien-17-one; 3-Hydroxyoestra-1,3,5(10)-trien-17-one; AB00382990; CS-0694877; E7378; Estrone Solution in Acetonitrile, 100ug/mL; Estrone, VETRANAL(TM), analytical standard; EU-0100513; NS00010299; Estrone Solution in Acetonitrile, 1000ug/mL; C00468; D00067; EN300-120636; AB00382990-16; AB00382990-17; AB00382990_18; estra-1(10),2,4-trien-17-one, 3-hydroxy-; ETHINYLESTRADIOL IMPURITY C [EP IMPURITY]; F301492; Q414986; SR-01000000085; SR-01000075867; SR-01000000085-3; SR-01000075867-1; BRD-K81839095-001-04-6; BRD-K81839095-001-25-1; BRD-K81839095-001-30-1; ESTRADIOL HEMIHYDRATE IMPURITY A [EP IMPURITY]; 86C77018-146D-4603-ACEA-CA0D8C4F1E2C; Estrone, European Pharmacopoeia (EP) Reference Standard; Z1530425070; Estrone, United States Pharmacopeia (USP) Reference Standard; Estrone, Pharmaceutical Secondary Standard; Certified Reference Material; (8R,13S)-3-Hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-cyclopenta[a]phenanthren-17-one; (8R,9S,13S,14S)-3-HYDROXY-13-METHYL-6,7,8,9,11,12,13,14,15,16-DECAHYDRO-17H-CYCLOPENTA(A)PHENANTHREN-17-ONE; Estradiol Hemihydrate EP Impurity A; Estriol EP Impurity B; Ethinylestradiol EP Impurity C; EstroneSynonyme